



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil

Infection with SARS-CoV-2 during pregnancy increases the risk of severe negative maternal and foetal clinical outcomes.¹ In the general population, the SARS-CoV-2 B.1.1.529 (omicron) variant can evade both natural and vaccine-induced protection,² highlighting the importance of booster doses.³ However, little is known about the vaccine effectiveness of a booster dose against COVID-19 in pregnant people, and no data have been published for those with a primary series of CoronaVac (inactivated-virus vaccine).^{4,5} In this study, we investigated the vaccine effectiveness in pregnant people who received two doses of CoronaVac to estimate the additional protection provided by a booster dose with BNT162b2 (mRNA vaccine) during the omicron period.

We conducted a test-negative design study on pregnant people who had a SARS-CoV-2 RT-PCR or an antigen test aged 15–49 years in Brazil, from Jan 1 to April 30, 2022 (appendix pp 2–4).^{6,7} Pregnancy information was abstracted from COVID-19 notifications from the national surveillance system for RT-PCR and antigen tests for COVID-19 infection (e-SUS Notifica) and the information system for severe acute respiratory illness (SIVEP-Gripe). Inclusion and exclusion criteria are described in the appendix (pp 2–4). Briefly, cases consisted of symptomatic pregnant people with a positive test (SARS-CoV-2 RT-PCR or antigen), and controls were pregnant individuals with a negative SARS-CoV-2 RT-PCR or antigen test. Individuals who were hospitalised or died from COVID-19 infection were classified as severe

	Tested positive (n=6280)	Severe cases* (n=434)	Tested negative (n=4506)	Vaccine effectiveness for symptomatic infection (95% CI)	Vaccine effectiveness for severe cases (95% CI)
Two doses of CoronaVac only					
≥14 days	5036 (80.2%)	381 (87.8%)	3156 (70.0%)	Reference	Reference
BNT162b2 booster dose					
0–13 days	194 (3.1%)	16 (3.7%)	188 (4.2%)	46.4% (33.2–57.0%)	43.2% (1.7–67.2%)
≥14 days	1050 (16.7%)	37 (8.5%)	1162 (25.8%)	37.7% (28.9–45.3%)	68.4% (52.6–78.9%)

The reference group were pregnant people vaccinated with two doses of CoronaVac at 14 days or less. *Severe cases include hospitalisations and deaths.

Table: Adjusted vaccine effectiveness against symptomatic infection and severe cases for pregnant people receiving a BNT162b2 booster dose (two doses of CoronaVac plus BNT162b2) at days 0–13 and 14 days or more

COVID-19. To attribute the death or hospitalisation to COVID-19, the hospitalisation had to have occurred 3 days before or 14 days after the positive test, and the death within 28 days of the positive test. Logistic regression was used to estimate the vaccine effectiveness of a booster dose compared with two doses of CoronaVac, both at 14 days or more after the last vaccination. The following confounders were included in the model: age, ethnicity, week of infection, the month when the second dose was received, region of residence, socioeconomic status, previous SARS-CoV-2 infection, and the presence of comorbidities. Detailed methods can be found in the appendix (p 2).

A total of 10786 tests were included, with 6280 (58.2%) testing positive (cases) and 4506 (41.8%) testing negative (controls; appendix p 4). Among the cases, 434 met the criteria for severity. Cases and controls had similar characteristics (appendix p 5). The adjusted vaccine effectiveness for a booster compared with primary complete vaccination in pregnant people was 37.7% (95% CI 28.9–45.3) against symptomatic COVID-19 and 68.4% (52.6–78.9%) against severe COVID-19 (table). Crude and adjusted odds ratios can be found in the appendix (p 6). Furthermore, the vaccine effectiveness was similar at 7 days or more compared to 14 days and more after the booster dose (appendix p 6).

The data collected in Brazil are from high-quality national databases, increasing their statistical power.^{6,7} The test-negative design is used to minimise bias related to access to health care, the occurrence of symptoms, and health-seeking behaviour. The primary assumption of the test-negative design is that people seeking and getting tested would be influenced by similar pressures, regardless of their vaccination status,⁸ and a limitation is the absence of information of pregnancy status at the time of vaccination and the precise gestational age at the time of testing.

Our findings strongly support the importance of a booster dose for pregnant people, because they provide additional maternal protection against mild and severe COVID-19 during the omicron period. Further studies are needed to assess the protection afforded by a booster dose in preventing negative foetal outcomes of COVID-19 for BNT162b2 and other COVID-19 vaccine regimens.

MB-N reports grants from the Fazer o bem faz bem program from JBS S.A. VdAO, VB, MLB, JC, and MB-N are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for public health use. All other authors declare no competing interests.

*Pilar T V Florentino, Flávia J O Alves, Thiago Cerqueira-Silva, Vinicius de Araújo Oliveira, Juracy B S Júnior, Gerson O Penna, Viviane Boaventura,



Lancet Infect Dis 2022

Published Online
November 7, 2022
[https://doi.org/10.1016/S1473-3099\(22\)00728-9](https://doi.org/10.1016/S1473-3099(22)00728-9)

See Online for appendix

Guilherme L Werneck, Neil Pearce,
Laura C Rodrigues, Mauricio L Barreto,
Manoel Barral-Netto, Enny S Paixão
pilar.veras@fiocruz.br

Centre of Data and Knowledge Integration for Health, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil (PTVF, FJOA, VdAO, MLB, MB-N); Biomedical Science Institute, University of São Paulo, São Paulo, 41745-715 Brazil (PTVF); Gonçalo Moniz Institute, Oswaldo Cruz Foundation (Fiocruz), Salvador, Brazil (TC-S, VB, MB-N); Faculty of Medicine, Federal University of Bahia School of Medicine, Salvador, Brazil (TC-S, VdAO, VB, MB-N); Public Health Institute, Federal University of Bahia, Salvador, Brazil (JBSJ); Tropical Medicine Centre, University of Brasília, Fiocruz School of Government, Brasília, Brazil (GOP); Department of Epidemiology, Social Medicine Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil (GLW); Institute of Collective Health Studies, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil (GLW); London School of Hygiene and Tropical Medicine, London, UK (NP, LCR, ESP)

- 1 Center for Disease Control and Prevention. COVID-19 vaccines while pregnant or breastfeeding. 2022. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html> (accessed April 19, 2022).
- 2 Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature* 2021; **602**: 654–56.
- 3 Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**: 255–63.
- 4 Schrag SJ, Verani JR, Dixon BE, et al. Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of delta and omicron variant predominance in the United States. *JAMA Netw Open* 2022; **5**: e2233273.
- 5 Guedalia J, Lipschuetz M, Calderon-Margalit R, et al. Effectiveness of BNT162b2 mRNA COVID-19 third vaccines during pregnancy: a national observational study in Israel. *SSRN* 2022; published online July 11. <https://doi.org/10.2139/ssrn.4159559> (preprint).
- 6 Katikireddi SV, Cerqueira-Silva T, Vasileiou E, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. *Lancet* 2022; **399**: 25–35.
- 7 Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. *Nat Commun* 2022; **13**: 4154.
- 8 Vandenbroucke JP, Brickley EB, Vandenbroucke-Grauls CMJE, Pearce N. A test-negative design with additional population controls can be used to rapidly study causes of the SARS-CoV-2 epidemic. *Epidemiology* 2020; **31**: 836–43.